Long non-coding RNA LINC-PINT is associated with favorable prognosis in cancer patients: a meta-analysis

Long non-coding RNA LINC-PINT is associated with favorable prognosis in cancer patients: a meta-analysis | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Long non-coding RNA LINC-PINT is associated with favorable prognosis in cancer patients: a meta-analysis Hyun Min Koh, Chang Lim Hyun, Dong Hui Lee, Sungjoon Park, Nayoung Han This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-3952451/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background There is growing evidence that long non-coding RNA long iatrogenic non-protein-coding RNA p53-induced transcript (LINC-PINT) is highly expressed in cancer tissue and is associated with the prognosis of cancer patients. The present study systematically analyzed the prognostic significance of LINC-PINT expression in cancer patients. Methods We collected eligible studies through the PubMed, Embase, and Cochrane library searches until February 1, 2024. The prognostic significance of LINC-PINT expression was evaluated by conducting a meta-analysis. Results Eleven eligible studies with 2876 cancer patients were collected. The pooled results revealed that LINC-PINT expression was associated with favorable overall survival (OS) and disease-free survival (DFS) in cancer patients (for OS, hazard ratio [HR] 0.72, 95% confidence interval [CI] 0.64–0.80, p < 0.001; for DFS, HR 0.70, 95% CI 0.60–0.82, p < 0.001). Conclusion LINC-PINT expression was associated with favorable OS and DFS, and it may serve as a valuable prognostic marker in cancer patients. Cancer LINC-PINT Long non-coding RNA Meta-analysis Prognosis Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Background Cancer has emerged as a major health problem worldwide. Despite several developments in cancer diagnosis and treatment, the survival rate of cancer patients remains low [ 1 ]. Therefore, it is imperative to develop biomarkers that can help in early diagnosis and prognostic stratification, and serve as therapeutic targets for cancer patients [ 2 ]. Long non-coding RNAs (lncRNAs) are defined as non-coding RNAs longer than 200 nucleotides [ 3 ]. LncRNAs regulate local protein-coding gene expression at the level of chromatin remodeling, transcriptional control, and post-transcriptional processing [ 4 ]. There is increasing evidence for the involvement of lncRNAs in various human diseases due to aberrant lncRNA function in differentiation and developmental processes [ 3 , 4 ]. Recently, some lncRNAs have been identified as cancer-related molecules [ 5 ]. The lncRNA long iatrogenic non-protein-coding RNA p53-induced transcript (LINC-PINT) is abnormally expressed in various cancer [ 6 ]. Moreover, lncRNA LINC-PINT is identified tumor suppressor with down regulated expression in many types of cancer cells [ 7 ]. Furthermore, current studies have demonstrated that LINC-PINT is associated with prognosis in cancer patients, but its exact prognostic role has not been quantitatively investigated [ 6 – 16 ]. Hence, we integrated eligible studies to explore the relationship between lncRNA LINC-PINT expression and the prognosis of cancer patients. Methods Literature search We searched eligible studies through the PubMed, Embase, and Cochrane library searches until February 1, 2024 using the following terms: (LncRNA LINC-PINT or Long non-coding RNA LINC-PINT) and (cancer or tumor or carcinoma or neoplasm or malignancy) and (prognostic or predictive or prognosis or survival or outcome). We also performed a manual search. Inclusion and exclusion criteria We enrolled studies that coincide the following qualifications: (1) studies evaluating the relationship between LINC-PINT expression and survival, and (2) LINC-PINT expression evaluating in human cancer tissue. Reviews, case reports, letters, conference abstracts, non-English articles, and duplicate articles were excluded. Data extraction Two authors individually collected the following data from the enrolled studies: first author, publication year, country, cancer type, case number, cancer stage, detection method and cut-off value of LINC-PINT expression, follow-up period, and survival outcome. Hazard ratio (HR) and 95% confidence interval (CI) were calculated from Kaplan-Meier plots. Differences in the data were agreed by reaching a consensus through a discussion. Quality assessment Two authors individually evaluated the quality of the enrolled studies by the Newcastle-Ottawa Scale (NOS). Differences in the quality evaluation were agreed by reaching a consensus through a discussion. Statistical analysis The relationship between LINC-PINT and survival outcome assessed by calculating HR with 95% CI. and the heterogeneity of the enrolled studies used I 2 statistics. The subgroup analysis was also evaluated. The funnel plot with Egger’s test was performed to check for publication, and the sensitivity analysis carried out to reveal the consistency of the pooled results. StataSE17 (Stata, College Station, TX, USA) was used for all analyses. The p value < 0.05 was considered statistically significant. Results Study characteristics We reviewed a total of 86 articles and selected eleven eligible studies (Fig. 1 ). The basic data of the enrolled studies are shown in Table 1 . All studies were published in China, and the publication years ranged from 2016 to 2021. Enrolled cases included gastric cancer (n = 2), laryngeal squamous cell carcinoma (n = 1), lung cancer (n = 1), glioblastoma (n = 1), breast cancer (n = 1), ovarian cancer (n = 1), renal cancer (n = 1), melanoma (n = 1), esophageal cancer (n = 1), and pancreatic cancer (n = 1). These studies enrolled a total of 2876 cancer patients. The NOS scores of the included studies suggested relatively good quality, ranging from 7 to 8. Table 1 Characteristics of studies enrolled in this meta-analysis. Study Country Cancer type Case number (high/low) Stage (case number) Detection method Cut-off value Follow-up (months) Survival outcome Survival analysis NOS Yang et al (2021) China Laryngeal squamous cell carcinoma 15/15 I-II/III-IV (12/18) RT-PCR median 40 OS KM 7 Zhang et al (2021) China NSCLC 58/64 I-II/III-IV (56/66) RT-PCR NR 60 OS KM, MVA 8 Zhu et al (2021) China Glioblastoma 338/338 NR GEPIA database NR 200 OS, DFS KM 7 Chen et al (2020) China Breast cancer 535/535 NR GEPIA database NR 300 OS, DFS KM 7 Hao et al (2020) China Ovarian cancer 20/52 I-II/III-IV (39/33) RT-PCR NR 120 OS KM 7 Duan et al (2019) China CCRCC 41/41 I-II/III-IV (69/13) RT-PCR median 60 OS, DFS KM 7 Feng et al (2019) China Gastric cancer 33/39 I-II/III-IV (19/53) RT-PCR using OriginLab software 60 OS KM 7 Hong et al (2019) China Gastric cancer 38/40 NR RT-PCR Youden’s index 60 OS KM 7 Xu et al (2019) China Melanoma 138/138 NR RT-PCR NR 400 OS, DFS KM 7 Zhang et al (2019) China Esophageal cancer 67/270 T1-T2/T3 (257/80) RT-PCR NR 40 OS KM 7 Li et al (2016) China Pancreatic cancer NR I-II/III-IV (35/26) RT-PCR NR 60 OS KM, MVA 8 CCRCC, clear cell renal cell carcinoma; DFS, disease-free survival; KM, Kaplan Meier; MVA, multivariate analysis; NR, no report; NOS, Newcastle-Ottawa Scale; NSCLC, non-small cell lung cancer; OS, overall survival; RT-PCR, reverse transcription PCR. Association between LINC-PINT expression and overall survival Eleven studies with a total of 2876 cancer patients assessed a relationship between LINC-PINT expression and overall survival (OS). The heterogeneity (I 2 = 44.86%, p = 0.05) between the studies was moderate that the pooled HR was evaluated by the fixed effects model. The pooled HR was 0.72 (95% CI 0.64–0.80, p < 0.001), suggesting that LINC-PINT expression was associated to favorable OS (Fig. 2 ). In the subgroup analysis of cancer type and case number, the groups with non-digestive system cancer (HR 0.74, 95% CI 0.66–0.83, p < 0.001) and digestive system cancer (HR 0.61, 95% CI 0.46–0.81, p = 0.001), and the groups with case number 100 (HR 0.74, 95% CI 0.66–0.83, p < 0.001) were statistically significant (Table 2 ) (Fig. 3AB) Table 2 Subgroup analysis of the association between LINC-PINT expression and overall survival in cancer patients. Heterogeneity Subgroup Number of studies Number of patients Pooled HR (95% CI) p value I 2 (%) p value Cancer type Non- Digestive system cancer 7 2328 0.74 (0.66–0.83) < 0.001 49.30 0.07 Digestive system cancer 4 548 0.61 (0.46–0.81) 0.001 38.07 0.18 Case number Less than 100 6 395 0.56 (0.40–0.79) 0.001 24.90 0.25 More than 100 5 2481 0.74 (0.66–0.83) < 0.001 56.60 0.06 CI, confidence interval; HR, hazard ratio. Association between LINC-PINT expression and disease-free survival Four studies with a total of 2104 cancer patients evaluated a relationship between LINC-PINT expression and disease-free survival (DFS). The heterogeneity (I 2 = 14.52%, p = 0.32) between the studies was low that the pooled HR was assessed by the fixed effects model. The pooled HR was 0.70 (95% CI 0.60–0.82, p < 0.001), implying that LINC-PINT expression was associated to favorable DFS (Fig. 4 ). Publication bias Funnel plot with Egger’s test was performed to know for publication bias. For OS, funnel plot showed slightly asymmetric appearance, but the Egger’s test revealed that it was not statistically significant (p = 0.145) (Fig. 5 A). For DFS, funnel test with Egger’s test was not significant (p = 0.345) (Fig. 5 B). The trim and fill methods were also evaluated. The pooled results were still significant for OS (HR 0.75, 95% CI 0.67–0.83) and for DFS (HR 0.69, 95% CI 0.59–0.81), showing that our initial pooled results were consistent (Fig. 6AB). e Sensitivity analysis The sensitivity analysis was performed that the enrolled studies were omitted one by one to assess the effect of the studies. The results showed that the pooled HR was not significantly affected by any single study for OS (HR 0.72, 95% CI 0.64–0.80, p < 0.001) and for DFS (HR 0.70, 95% CI 0.60–0.82, p 200 nucleotides in length, with no protein translating potential [ 17 ]. Although they are not translated, lncRNAs have important functions in various biological processes, such as gene regulation and expression, chromatin dynamics, and cellular growth and differentiation [ 17 ]. Recently, the aberrant function of lncRNAs was linked to many cancers and diseases [ 18 ]. LINC-PINT, a novel lncRNA, has been identified to be expressed in multiple cancers, and is believed to be related to the prognosis of cancer patients [ 6 ]. For example, the expression of LINC-PINT was demonstrated to suppress the malignant progression of cancer cells in non-small cell cancer [ 6 ], triple negative breast cancer [ 8 ], gastric cancer [ 7 , 11 ], ovarian cancer [ 10 ], pancreatic cancer [ 12 ], melanoma [ 13 ] and laryngeal squamous cell carcinoma [ 14 ] as well as esophageal cancer [ 15 ] and glioblastoma [ 16 ]. LINC-PINT expression has also been associated with prognosis in lung, gastric, breast, ovarian, pancreatic, esophageal, laryngeal, renal, brain cancer, and melanoma [ 6 – 16 ]. In this study, we collected eleven related studies and conducted a meta-analysis. We reported the prognostic significance of LINC-PINT expression in cancer patients. We proved that LINC-PINT expression was significantly related to OS and DFS. Regarding the cancer type and case number, the results were statistically significant. Most of the studies we collected showed that LINC-PINT expression was associated with favorable survival. Only one study [ 9 ] reported that high expression of LINC-PINT was significantly correlated with poor clinical outcomes in patients with clear cell renal cell carcinoma. They advocated that overexpression of LINC-PINT promoted cancer cell proliferation, induced cell cycle progression, and inhibited apoptosis [ 9 ]. Therefore, we hope that future research will clarify the effects of LINC-PINT on cancer. The study had some limitations. First, all studies were published in China. Therefore, these results may not be necessarily applicable to other regions. Second, cancer type and case number were small, which led to the inaccuracy of our results. Third, HRs with CIs were calculated by processing survival curves, thus the prognostic significance of LINC-PINT expression might be exaggerated. In conclusion, this study was the first to demonstrate the prognostic significance of LINC-PINT expression in cancer patients. High expression of LINC-PINT was associated with favorable OS and DFS, and it may serve as a valuable prognostic marker in cancer patients. Declarations Ethics approval and consent to participate Not applicable Consent for publication Not applicable Availability of data and materials All the data used to support the findings of this study are included within the article. Competing interests The authors declare that they have no competing interests. Funding This work was supported by a research grant from Jeju National University Hospital in 2022. Authors’ contributions Hyun Min Koh: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Writing - original draft Chang Lim Hyun: Conceptualization, Data curation, Formal analysis, Writing - Reviewing and Editing Dong Hui Lee: Validation, Writing - Reviewing and Editing Sungjoon Park: Validation, Writing - Reviewing and Editing Nayoung Han: Conceptualization, Resources, Supervision, Validation, Writing - Reviewing and Editing Acknowledgements We would like to thank the researchers and study participants for their contributions References Yu H, Li S, Wu S, Huang S, Li S, Ye L. The prognostic value of long non-coding RNA H19 in various cancers: a meta-analysis based on 15 studies with 1584 patients and the Cancer Genome Atlas data. Medicine 2020, 99(2). Dong B, Chen X, Zhang Y, Zhu C, Dong Q. The prognostic value of lncRNA SNHG1 in cancer patients: a meta-analysis. BMC Cancer. 2019;19(1):1–8. Marchese FP, Raimondi I, Huarte M. The multidimensional mechanisms of long noncoding RNA function. Genome Biol. 2017;18:1–13. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10(3):155–9. Qiu M, Hu J, Yin R, Xu L. Long noncoding RNA: an emerging paradigm of cancer research. Tumor Biol. 2013;34:613–20. Zhang C, Gong C, Li J, Tang J. Downregulation of long noncoding RNA LINCPINT serves as a diagnostic and prognostic biomarker in patients with nonsmall cell lung cancer. Oncol Lett. 2021;21(3):1. Feng H, Zhang J, Shi Y, Wang L, Zhang C, Wu L. Long noncoding RNA LINC-PINT is inhibited in gastric cancer and predicts poor survival. J Cell Biochem. 2019;120(6):9594–600. Chen J, Zhu M, Zou L, Xia J, Huang J, Deng Q, Xu R. Long non-coding RNA LINC-PINT attenuates paclitaxel resistance in triple-negative breast cancer cells via targeting the RNA-binding protein NONO. Acta Biochim Biophys Sin. 2020;52(8):801–9. Duan J, Ma X, Shi J, Xuan Y, Wang H, Li P, Zhang Y, Fan Y, Gong H, Ma X. Long noncoding RNA LINC-PINT promotes proliferation through EZH2 and predicts poor prognosis in clear cell renal cell carcinoma. OncoTargets therapy 2019,:4729–40. Hao T, Huang S, Han F. LINC-PINT suppresses tumour cell proliferation, migration and invasion through targeting miR‐374a‐5p in ovarian cancer. Cell Biochem Funct. 2020;38(8):1089–99. Hong L, Wang H, Wang J, Wei S, Zhang F, Han J, Liu Y, Ma M, Liu C, Xu Y. LncRNA PTCSC3 inhibits tumor growth and cancer cell stemness in gastric cancer by interacting with lncRNA linc-pint. Cancer Manage Res 2019,:10393–9. Li L, Zhang G, Chen H, Zhao Z, Chen H, Liu H, Wang G, Jia Y, Pan S, Kong R. Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer. Oncotarget. 2016;7(44):71773. Xu Y, Wang H, Li F, Heindl LM, He X, Yu J, Yang J, Ge S, Ruan J, Jia R. Long non-coding RNA LINC-PINT suppresses cell proliferation and migration of melanoma via recruiting EZH2. Front cell Dev biology. 2019;7:350. Yang X, Miao S, Mao X, Xiu C, Sun J, Pei R, Jia S. LncRNA LINC-PINT inhibits malignant behaviors of laryngeal squamous cell carcinoma cells via inhibiting ZEB1. Pathol Oncol Res. 2021;27:584466. Zhang L, Chen J, Wang LI, Chen L, Du Z, Zhu L, Cui M, Zhang M, Song L. Linc-PINT acted as a tumor suppressor by sponging miR‐543 and miR‐576‐5p in esophageal cancer. J Cell Biochem. 2019;120(12):19345–57. Zhu H, Chen Z, Shen L, Tang T, Yang M, Zheng X. Long noncoding RNA LINC-PINT suppresses cell proliferation, invasion, and EMT by blocking Wnt/β-catenin signaling in glioblastoma. Front Pharmacol. 2021;11:586653. Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77(15):3965–81. Schmitt AM, Chang HY. Long noncoding RNAs: at the intersection of cancer and chromatin biology. Cold Spring Harbor Perspect Med. 2017;7(7):a026492. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-3952451","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":272781706,"identity":"dd6e0722-a5d2-430b-8a44-8f7dfa7c1935","order_by":0,"name":"Hyun Min Koh","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA0UlEQVRIiWNgGAWjYDACCQZmBsYGmwQwJ6GAeC1pUC0GQIKNOC2HIVoYiNEiP7v5sMHHHefz+Gd3J354YMCQxy/fgF+LwZ1jyYkzz9wulrhzdrME0GHFkm0EbDGQyDE+zNt2O7HhRu4GkJbEDccIOWxG/meglnOJ82/kbv4B0rKfkBaGGznMybxtBxI33MjdBrGFkPcNbqQZG85sS07cCNRikWAgkTjjWAIhhyU/lvjYZpc4D+iwmz8qbBL7mw8QchkqkCBN+SgYBaNgFIwC7AAAp0xI/rLBpZsAAAAASUVORK5CYII=","orcid":"","institution":"Jeju National University School of Medicine","correspondingAuthor":true,"prefix":"","firstName":"Hyun","middleName":"Min","lastName":"Koh","suffix":""},{"id":272781707,"identity":"530eacb4-2531-4cd8-9a9f-0bd78beb6cca","order_by":1,"name":"Chang Lim Hyun","email":"","orcid":"","institution":"Jeju National University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Chang","middleName":"Lim","lastName":"Hyun","suffix":""},{"id":272781708,"identity":"d814b8a3-d98d-47ec-b5b3-cfbdf3fa40ce","order_by":2,"name":"Dong Hui Lee","email":"","orcid":"","institution":"Jeju National University Hospital","correspondingAuthor":false,"prefix":"","firstName":"Dong","middleName":"Hui","lastName":"Lee","suffix":""},{"id":272781709,"identity":"a221b0b4-db89-4390-a300-64d6884e5a34","order_by":3,"name":"Sungjoon Park","email":"","orcid":"","institution":"Jeju National University Hospital","correspondingAuthor":false,"prefix":"","firstName":"Sungjoon","middleName":"","lastName":"Park","suffix":""},{"id":272781710,"identity":"b3936bbe-3a3a-4626-8ed7-cb04cebec326","order_by":4,"name":"Nayoung Han","email":"","orcid":"","institution":"Jeju National University","correspondingAuthor":false,"prefix":"","firstName":"Nayoung","middleName":"","lastName":"Han","suffix":""}],"badges":[],"createdAt":"2024-02-13 02:35:11","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-3952451/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-3952451/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":51197048,"identity":"1cb6fdd9-1c85-413a-b9be-dfd83395a150","added_by":"auto","created_at":"2024-02-15 19:01:00","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":27836,"visible":true,"origin":"","legend":"\u003cp\u003eFlow diagram of the study selection.\u003c/p\u003e","description":"","filename":"OnlineFigure113.png","url":"https://assets-eu.researchsquare.com/files/rs-3952451/v1/8a2b91f9fc0cfcbe047c9423.png"},{"id":51197049,"identity":"4c96595c-e5c4-497e-bb95-8d065ced2196","added_by":"auto","created_at":"2024-02-15 19:01:00","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":36017,"visible":true,"origin":"","legend":"\u003cp\u003eForest plot of the association between LINC-PINT expression and overall survival.\u003c/p\u003e","description":"","filename":"OnlineFigure211.png","url":"https://assets-eu.researchsquare.com/files/rs-3952451/v1/6ee3394c8563dd32f3e26e11.png"},{"id":51197047,"identity":"23b73f37-d482-484d-950d-559418d126b1","added_by":"auto","created_at":"2024-02-15 19:01:00","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":126765,"visible":true,"origin":"","legend":"\u003cp\u003eForest plot of the association between LINC-PINT expression and overall survival stratified by cancer type (A) and case number (B).\u003c/p\u003e","description":"","filename":"OnlineFigure3A1.png","url":"https://assets-eu.researchsquare.com/files/rs-3952451/v1/de8c00d311fd5d6db95ecd8f.png"},{"id":51197046,"identity":"79cae997-d153-40a1-ab0a-b61279610d67","added_by":"auto","created_at":"2024-02-15 19:01:00","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":20280,"visible":true,"origin":"","legend":"\u003cp\u003eForest plot of the association between LINC-PINT expression and disease-free survival.\u003c/p\u003e","description":"","filename":"OnlineFigure49.png","url":"https://assets-eu.researchsquare.com/files/rs-3952451/v1/f54a2c15c4c07a0b992fa72a.png"},{"id":51197052,"identity":"d6b3a768-4abc-4d40-9bf9-d748c8287ad1","added_by":"auto","created_at":"2024-02-15 19:01:01","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":55786,"visible":true,"origin":"","legend":"\u003cp\u003eFunnel plot of the association between LINC-PINT expression with overall survival (A) and disease-free survival (B).\u003c/p\u003e","description":"","filename":"OnlineFigure5A.png","url":"https://assets-eu.researchsquare.com/files/rs-3952451/v1/d582f281aae3e7c83609cedd.png"},{"id":51197050,"identity":"d87e23b7-2abf-4b5d-a786-d835c0937421","added_by":"auto","created_at":"2024-02-15 19:01:00","extension":"png","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":47754,"visible":true,"origin":"","legend":"\u003cp\u003eTrim and fill method of the association between LINC-PINT expression with overall survival (A) and disease-free survival (B).\u003c/p\u003e","description":"","filename":"OnlineFigure6A.png","url":"https://assets-eu.researchsquare.com/files/rs-3952451/v1/8065a400ee48dc98f1cfea24.png"},{"id":51197051,"identity":"1ab03474-c2e8-42eb-aca0-2b18424759f4","added_by":"auto","created_at":"2024-02-15 19:01:01","extension":"png","order_by":7,"title":"Figure 7","display":"","copyAsset":false,"role":"figure","size":122329,"visible":true,"origin":"","legend":"\u003cp\u003eSensitivity analysis of the association between LINC-PINT expression with overall survival (A) and disease-free survival (B).\u003c/p\u003e","description":"","filename":"OnlineFigure7A.png","url":"https://assets-eu.researchsquare.com/files/rs-3952451/v1/69f38f431fcff8e3b852bb9b.png"},{"id":54504247,"identity":"4294f726-50ed-47c9-b8f6-f245d8e67a72","added_by":"auto","created_at":"2024-04-11 13:51:10","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":924242,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-3952451/v1/7141bc67-87df-46de-b1e3-e9602cf38b00.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Long non-coding RNA LINC-PINT is associated with favorable prognosis in cancer patients: a meta-analysis","fulltext":[{"header":"Background","content":"\u003cp\u003eCancer has emerged as a major health problem worldwide. Despite several developments in cancer diagnosis and treatment, the survival rate of cancer patients remains low [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. Therefore, it is imperative to develop biomarkers that can help in early diagnosis and prognostic stratification, and serve as therapeutic targets for cancer patients [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eLong non-coding RNAs (lncRNAs) are defined as non-coding RNAs longer than 200 nucleotides [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. LncRNAs regulate local protein-coding gene expression at the level of chromatin remodeling, transcriptional control, and post-transcriptional processing [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. There is increasing evidence for the involvement of lncRNAs in various human diseases due to aberrant lncRNA function in differentiation and developmental processes [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eRecently, some lncRNAs have been identified as cancer-related molecules [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. The lncRNA long iatrogenic non-protein-coding RNA p53-induced transcript (LINC-PINT) is abnormally expressed in various cancer [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. Moreover, lncRNA LINC-PINT is identified tumor suppressor with down regulated expression in many types of cancer cells [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. Furthermore, current studies have demonstrated that LINC-PINT is associated with prognosis in cancer patients, but its exact prognostic role has not been quantitatively investigated [\u003cspan additionalcitationids=\"CR7 CR8 CR9 CR10 CR11 CR12 CR13 CR14 CR15\" citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. Hence, we integrated eligible studies to explore the relationship between lncRNA LINC-PINT expression and the prognosis of cancer patients.\u003c/p\u003e"},{"header":"Methods","content":"\u003cp\u003eLiterature search\u003c/p\u003e \u003cp\u003eWe searched eligible studies through the PubMed, Embase, and Cochrane library searches until February 1, 2024 using the following terms: (LncRNA LINC-PINT or Long non-coding RNA LINC-PINT) and (cancer or tumor or carcinoma or neoplasm or malignancy) and (prognostic or predictive or prognosis or survival or outcome). We also performed a manual search.\u003c/p\u003e \u003cp\u003eInclusion and exclusion criteria\u003c/p\u003e \u003cp\u003eWe enrolled studies that coincide the following qualifications: (1) studies evaluating the relationship between LINC-PINT expression and survival, and (2) LINC-PINT expression evaluating in human cancer tissue. Reviews, case reports, letters, conference abstracts, non-English articles, and duplicate articles were excluded.\u003c/p\u003e \u003cp\u003eData extraction\u003c/p\u003e \u003cp\u003eTwo authors individually collected the following data from the enrolled studies: first author, publication year, country, cancer type, case number, cancer stage, detection method and cut-off value of LINC-PINT expression, follow-up period, and survival outcome. Hazard ratio (HR) and 95% confidence interval (CI) were calculated from Kaplan-Meier plots. Differences in the data were agreed by reaching a consensus through a discussion.\u003c/p\u003e \u003cp\u003eQuality assessment\u003c/p\u003e \u003cp\u003eTwo authors individually evaluated the quality of the enrolled studies by the Newcastle-Ottawa Scale (NOS). Differences in the quality evaluation were agreed by reaching a consensus through a discussion.\u003c/p\u003e \u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eStatistical analysis\u003c/h2\u003e \u003cp\u003eThe relationship between LINC-PINT and survival outcome assessed by calculating HR with 95% CI. and the heterogeneity of the enrolled studies used I\u003csup\u003e2\u003c/sup\u003e statistics. The subgroup analysis was also evaluated. The funnel plot with Egger\u0026rsquo;s test was performed to check for publication, and the sensitivity analysis carried out to reveal the consistency of the pooled results. StataSE17 (Stata, College Station, TX, USA) was used for all analyses. The p value\u0026thinsp;\u0026lt;\u0026thinsp;0.05 was considered statistically significant.\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cp\u003eStudy characteristics\u003c/p\u003e \u003cp\u003eWe reviewed a total of 86 articles and selected eleven eligible studies (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). The basic data of the enrolled studies are shown in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e. All studies were published in China, and the publication years ranged from 2016 to 2021. Enrolled cases included gastric cancer (n\u0026thinsp;=\u0026thinsp;2), laryngeal squamous cell carcinoma (n\u0026thinsp;=\u0026thinsp;1), lung cancer (n\u0026thinsp;=\u0026thinsp;1), glioblastoma (n\u0026thinsp;=\u0026thinsp;1), breast cancer (n\u0026thinsp;=\u0026thinsp;1), ovarian cancer (n\u0026thinsp;=\u0026thinsp;1), renal cancer (n\u0026thinsp;=\u0026thinsp;1), melanoma (n\u0026thinsp;=\u0026thinsp;1), esophageal cancer (n\u0026thinsp;=\u0026thinsp;1), and pancreatic cancer (n\u0026thinsp;=\u0026thinsp;1). These studies enrolled a total of 2876 cancer patients. The NOS scores of the included studies suggested relatively good quality, ranging from 7 to 8.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eCharacteristics of studies enrolled in this meta-analysis.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"11\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c10\" colnum=\"10\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c11\" colnum=\"11\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eStudy\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCountry\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eCancer type\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eCase number (high/low)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eStage\u003c/p\u003e \u003cp\u003e(case number)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eDetection method\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003eCut-off value\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c8\"\u003e \u003cp\u003eFollow-up (months)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c9\"\u003e \u003cp\u003eSurvival outcome\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c10\"\u003e \u003cp\u003eSurvival analysis\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c11\"\u003e \u003cp\u003eNOS\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYang et al (2021)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eLaryngeal squamous cell carcinoma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e15/15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eI-II/III-IV (12/18)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eRT-PCR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003emedian\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e40\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eOS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eKM\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c11\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eZhang et al (2021)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNSCLC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e58/64\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eI-II/III-IV (56/66)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eRT-PCR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eOS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eKM, MVA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c11\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eZhu et al (2021)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eGlioblastoma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e338/338\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eGEPIA database\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e200\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eOS, DFS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eKM\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c11\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eChen et al (2020)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eBreast cancer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e535/535\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eGEPIA database\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e300\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eOS, DFS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eKM\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c11\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHao et al (2020)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eOvarian cancer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e20/52\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eI-II/III-IV (39/33)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eRT-PCR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e120\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eOS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eKM\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c11\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDuan et al (2019)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eCCRCC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e41/41\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eI-II/III-IV (69/13)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eRT-PCR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003emedian\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eOS, DFS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eKM\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c11\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFeng et al (2019)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eGastric cancer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e33/39\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eI-II/III-IV (19/53)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eRT-PCR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eusing OriginLab software\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eOS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eKM\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c11\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHong et al (2019)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eGastric cancer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e38/40\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eRT-PCR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eYouden\u0026rsquo;s index\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eOS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eKM\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c11\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eXu et al (2019)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eMelanoma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e138/138\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eRT-PCR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e400\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eOS, DFS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eKM\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c11\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eZhang et al (2019)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eEsophageal cancer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e67/270\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eT1-T2/T3 (257/80)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eRT-PCR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e40\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eOS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eKM\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c11\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLi et al (2016)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003ePancreatic cancer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eI-II/III-IV (35/26)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eRT-PCR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eOS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eKM, MVA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c11\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"11\"\u003eCCRCC, clear cell renal cell carcinoma; DFS, disease-free survival; KM, Kaplan Meier; MVA, multivariate analysis; NR, no report; NOS, Newcastle-Ottawa Scale; NSCLC, non-small cell lung cancer; OS, overall survival; RT-PCR, reverse transcription PCR.\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eAssociation between LINC-PINT expression and overall survival\u003c/p\u003e \u003cp\u003eEleven studies with a total of 2876 cancer patients assessed a relationship between LINC-PINT expression and overall survival (OS). The heterogeneity (I\u003csup\u003e2\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;44.86%, p\u0026thinsp;=\u0026thinsp;0.05) between the studies was moderate that the pooled HR was evaluated by the fixed effects model. The pooled HR was 0.72 (95% CI 0.64\u0026ndash;0.80, p\u0026thinsp;\u0026lt;\u0026thinsp;0.001), suggesting that LINC-PINT expression was associated to favorable OS (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e). In the subgroup analysis of cancer type and case number, the groups with non-digestive system cancer (HR 0.74, 95% CI 0.66\u0026ndash;0.83, p\u0026thinsp;\u0026lt;\u0026thinsp;0.001) and digestive system cancer (HR 0.61, 95% CI 0.46\u0026ndash;0.81, p\u0026thinsp;=\u0026thinsp;0.001), and the groups with case number\u0026thinsp;\u0026lt;\u0026thinsp;100 (HR 0.56, 95% CI 0.40\u0026ndash;0.79, p\u0026thinsp;=\u0026thinsp;0.001) and \u0026gt;\u0026thinsp;100 (HR 0.74, 95% CI 0.66\u0026ndash;0.83, p\u0026thinsp;\u0026lt;\u0026thinsp;0.001) were statistically significant (Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e) (Fig.\u0026nbsp;3AB)\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eSubgroup analysis of the association between LINC-PINT expression and overall survival in cancer patients.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"7\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003eHeterogeneity\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSubgroup\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNumber of studies\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNumber of patients\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ePooled HR (95% CI)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ep value\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eI\u003csup\u003e2\u003c/sup\u003e (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ep value\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCancer type\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNon- Digestive system cancer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2328\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.74 (0.66\u0026ndash;0.83)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e49.30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.07\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDigestive system cancer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e548\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.61 (0.46\u0026ndash;0.81)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e38.07\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.18\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCase number\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLess than 100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e395\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.56 (0.40\u0026ndash;0.79)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e24.90\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.25\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMore than 100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2481\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.74 (0.66\u0026ndash;0.83)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e56.60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.06\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"7\"\u003eCI, confidence interval; HR, hazard ratio.\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eAssociation between LINC-PINT expression and disease-free survival\u003c/p\u003e \u003cp\u003eFour studies with a total of 2104 cancer patients evaluated a relationship between LINC-PINT expression and disease-free survival (DFS). The heterogeneity (I\u003csup\u003e2\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;14.52%, p\u0026thinsp;=\u0026thinsp;0.32) between the studies was low that the pooled HR was assessed by the fixed effects model. The pooled HR was 0.70 (95% CI 0.60\u0026ndash;0.82, p\u0026thinsp;\u0026lt;\u0026thinsp;0.001), implying that LINC-PINT expression was associated to favorable DFS (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003e).\u003c/p\u003e \u003cp\u003ePublication bias\u003c/p\u003e \u003cp\u003eFunnel plot with Egger\u0026rsquo;s test was performed to know for publication bias. For OS, funnel plot showed slightly asymmetric appearance, but the Egger\u0026rsquo;s test revealed that it was not statistically significant (p\u0026thinsp;=\u0026thinsp;0.145) (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eA). For DFS, funnel test with Egger\u0026rsquo;s test was not significant (p\u0026thinsp;=\u0026thinsp;0.345) (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eB). The trim and fill methods were also evaluated. The pooled results were still significant for OS (HR 0.75, 95% CI 0.67\u0026ndash;0.83) and for DFS (HR 0.69, 95% CI 0.59\u0026ndash;0.81), showing that our initial pooled results were consistent (Fig.\u0026nbsp;6AB). e\u003c/p\u003e \u003cp\u003eSensitivity analysis\u003c/p\u003e \u003cp\u003eThe sensitivity analysis was performed that the enrolled studies were omitted one by one to assess the effect of the studies. The results showed that the pooled HR was not significantly affected by any single study for OS (HR 0.72, 95% CI 0.64\u0026ndash;0.80, p\u0026thinsp;\u0026lt;\u0026thinsp;0.001) and for DFS (HR 0.70, 95% CI 0.60\u0026ndash;0.82, p\u0026thinsp;\u0026lt;\u0026thinsp;0.001) (Fig.\u0026nbsp;7AB).\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eLncRNAs, a subset of non-coding RNAs, are defined as transcripts\u0026thinsp;\u0026gt;\u0026thinsp;200 nucleotides in length, with no protein translating potential [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e]. Although they are not translated, lncRNAs have important functions in various biological processes, such as gene regulation and expression, chromatin dynamics, and cellular growth and differentiation [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e]. Recently, the aberrant function of lncRNAs was linked to many cancers and diseases [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eLINC-PINT, a novel lncRNA, has been identified to be expressed in multiple cancers, and is believed to be related to the prognosis of cancer patients [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. For example, the expression of LINC-PINT was demonstrated to suppress the malignant progression of cancer cells in non-small cell cancer [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e], triple negative breast cancer [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e], gastric cancer [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e], ovarian cancer [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e], pancreatic cancer [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e], melanoma [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e] and laryngeal squamous cell carcinoma [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e] as well as esophageal cancer [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e] and glioblastoma [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. LINC-PINT expression has also been associated with prognosis in lung, gastric, breast, ovarian, pancreatic, esophageal, laryngeal, renal, brain cancer, and melanoma [\u003cspan additionalcitationids=\"CR7 CR8 CR9 CR10 CR11 CR12 CR13 CR14 CR15\" citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIn this study, we collected eleven related studies and conducted a meta-analysis. We reported the prognostic significance of LINC-PINT expression in cancer patients. We proved that LINC-PINT expression was significantly related to OS and DFS. Regarding the cancer type and case number, the results were statistically significant.\u003c/p\u003e \u003cp\u003eMost of the studies we collected showed that LINC-PINT expression was associated with favorable survival. Only one study [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e] reported that high expression of LINC-PINT was significantly correlated with poor clinical outcomes in patients with clear cell renal cell carcinoma. They advocated that overexpression of LINC-PINT promoted cancer cell proliferation, induced cell cycle progression, and inhibited apoptosis [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. Therefore, we hope that future research will clarify the effects of LINC-PINT on cancer.\u003c/p\u003e \u003cp\u003eThe study had some limitations. First, all studies were published in China. Therefore, these results may not be necessarily applicable to other regions. Second, cancer type and case number were small, which led to the inaccuracy of our results. Third, HRs with CIs were calculated by processing survival curves, thus the prognostic significance of LINC-PINT expression might be exaggerated.\u003c/p\u003e \u003cp\u003eIn conclusion, this study was the first to demonstrate the prognostic significance of LINC-PINT expression in cancer patients. High expression of LINC-PINT was associated with favorable OS and DFS, and it may serve as a valuable prognostic marker in cancer patients.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll the data used to support the findings of this study are included within the article.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that they have no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis work was supported by a research grant from Jeju National University Hospital in 2022.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026rsquo; contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eHyun Min Koh: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Writing - original draft \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eChang Lim Hyun:\u0026nbsp;Conceptualization, Data curation, Formal analysis, Writing - Reviewing and Editing\u003c/p\u003e\n\u003cp\u003eDong Hui Lee:\u0026nbsp;Validation, Writing - Reviewing and Editing\u003c/p\u003e\n\u003cp\u003eSungjoon Park:\u0026nbsp;Validation, Writing - Reviewing and Editing\u003c/p\u003e\n\u003cp\u003eNayoung Han: Conceptualization, Resources, Supervision, Validation, Writing - Reviewing and Editing\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe would like to thank the researchers and study participants for their contributions\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eYu H, Li S, Wu S, Huang S, Li S, Ye L. The prognostic value of long non-coding RNA H19 in various cancers: a meta-analysis based on 15 studies with 1584 patients and the Cancer Genome Atlas data. Medicine 2020, 99(2).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDong B, Chen X, Zhang Y, Zhu C, Dong Q. The prognostic value of lncRNA SNHG1 in cancer patients: a meta-analysis. BMC Cancer. 2019;19(1):1\u0026ndash;8.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMarchese FP, Raimondi I, Huarte M. The multidimensional mechanisms of long noncoding RNA function. Genome Biol. 2017;18:1\u0026ndash;13.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10(3):155\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eQiu M, Hu J, Yin R, Xu L. Long noncoding RNA: an emerging paradigm of cancer research. Tumor Biol. 2013;34:613\u0026ndash;20.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang C, Gong C, Li J, Tang J. Downregulation of long noncoding RNA LINCPINT serves as a diagnostic and prognostic biomarker in patients with nonsmall cell lung cancer. Oncol Lett. 2021;21(3):1.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFeng H, Zhang J, Shi Y, Wang L, Zhang C, Wu L. Long noncoding RNA LINC-PINT is inhibited in gastric cancer and predicts poor survival. J Cell Biochem. 2019;120(6):9594\u0026ndash;600.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChen J, Zhu M, Zou L, Xia J, Huang J, Deng Q, Xu R. Long non-coding RNA LINC-PINT attenuates paclitaxel resistance in triple-negative breast cancer cells via targeting the RNA-binding protein NONO. Acta Biochim Biophys Sin. 2020;52(8):801\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDuan J, Ma X, Shi J, Xuan Y, Wang H, Li P, Zhang Y, Fan Y, Gong H, Ma X. Long noncoding RNA LINC-PINT promotes proliferation through EZH2 and predicts poor prognosis in clear cell renal cell carcinoma. OncoTargets therapy 2019,:4729\u0026ndash;40.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHao T, Huang S, Han F. LINC-PINT suppresses tumour cell proliferation, migration and invasion through targeting miR‐374a‐5p in ovarian cancer. Cell Biochem Funct. 2020;38(8):1089\u0026ndash;99.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHong L, Wang H, Wang J, Wei S, Zhang F, Han J, Liu Y, Ma M, Liu C, Xu Y. LncRNA PTCSC3 inhibits tumor growth and cancer cell stemness in gastric cancer by interacting with lncRNA linc-pint. Cancer Manage Res 2019,:10393\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi L, Zhang G, Chen H, Zhao Z, Chen H, Liu H, Wang G, Jia Y, Pan S, Kong R. Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer. Oncotarget. 2016;7(44):71773.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eXu Y, Wang H, Li F, Heindl LM, He X, Yu J, Yang J, Ge S, Ruan J, Jia R. Long non-coding RNA LINC-PINT suppresses cell proliferation and migration of melanoma via recruiting EZH2. Front cell Dev biology. 2019;7:350.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYang X, Miao S, Mao X, Xiu C, Sun J, Pei R, Jia S. LncRNA LINC-PINT inhibits malignant behaviors of laryngeal squamous cell carcinoma cells via inhibiting ZEB1. Pathol Oncol Res. 2021;27:584466.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang L, Chen J, Wang LI, Chen L, Du Z, Zhu L, Cui M, Zhang M, Song L. Linc-PINT acted as a tumor suppressor by sponging miR‐543 and miR‐576‐5p in esophageal cancer. J Cell Biochem. 2019;120(12):19345\u0026ndash;57.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhu H, Chen Z, Shen L, Tang T, Yang M, Zheng X. Long noncoding RNA LINC-PINT suppresses cell proliferation, invasion, and EMT by blocking Wnt/β-catenin signaling in glioblastoma. Front Pharmacol. 2021;11:586653.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77(15):3965\u0026ndash;81.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSchmitt AM, Chang HY. Long noncoding RNAs: at the intersection of cancer and chromatin biology. Cold Spring Harbor Perspect Med. 2017;7(7):a026492.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Cancer, LINC-PINT, Long non-coding RNA, Meta-analysis, Prognosis","lastPublishedDoi":"10.21203/rs.3.rs-3952451/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-3952451/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e \u003cp\u003eThere is growing evidence that long non-coding RNA long iatrogenic non-protein-coding RNA p53-induced transcript (LINC-PINT) is highly expressed in cancer tissue and is associated with the prognosis of cancer patients. The present study systematically analyzed the prognostic significance of LINC-PINT expression in cancer patients.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eWe collected eligible studies through the PubMed, Embase, and Cochrane library searches until February 1, 2024. The prognostic significance of LINC-PINT expression was evaluated by conducting a meta-analysis.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eEleven eligible studies with 2876 cancer patients were collected. The pooled results revealed that LINC-PINT expression was associated with favorable overall survival (OS) and disease-free survival (DFS) in cancer patients (for OS, hazard ratio [HR] 0.72, 95% confidence interval [CI] 0.64\u0026ndash;0.80, p\u0026thinsp;\u0026lt;\u0026thinsp;0.001; for DFS, HR 0.70, 95% CI 0.60\u0026ndash;0.82, p\u0026thinsp;\u0026lt;\u0026thinsp;0.001).\u003c/p\u003e\u003ch2\u003eConclusion\u003c/h2\u003e \u003cp\u003eLINC-PINT expression was associated with favorable OS and DFS, and it may serve as a valuable prognostic marker in cancer patients.\u003c/p\u003e","manuscriptTitle":"Long non-coding RNA LINC-PINT is associated with favorable prognosis in cancer patients: a meta-analysis","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-02-15 19:00:55","doi":"10.21203/rs.3.rs-3952451/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"d29e1bf9-b7d1-443c-a350-a89b6730b900","owner":[],"postedDate":"February 15th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2024-04-11T13:43:05+00:00","versionOfRecord":[],"versionCreatedAt":"2024-02-15 19:00:55","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-3952451","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-3952451","identity":"rs-3952451","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}